Qed Therapeutics, A Bridgebio Company
Clinical trials sponsored by Qed Therapeutics, A Bridgebio Company, explained in plain language.
-
New hope for kids with dwarfism: daily pill may boost growth
Disease control ENROLLING_BY_INVITATIONThis study tests a daily pill called infigratinib in children with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth over several years. About 300 children who were in earlier studies or are new to the drug will take part. Because t…
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 26, 2026 08:08 UTC
-
New drug shows promise for helping children with rare bone disorder grow taller
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a daily pill called infigratinib for children with hypochondroplasia, a condition that causes short stature. About 135 children who previously took part in related studies will receive the drug for up to several years.…
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New drug aims to boost growth in kids with rare bone disorder
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called infigratinib in 24 children with hypochondroplasia, a condition that causes short stature. The goal is to see if it can safely improve growth rate. The study has two phases: first, all children get the drug, then some get a placebo to compare result…
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated May 15, 2026 11:54 UTC